Prophylactic vaccination with MCMV-TRP2 yielded striking outcomes, resulting in the rejection of B16-F10 melanoma cells and the establishment of long-term protection against B16 melanoma challenge regardless of prior CMV infection. The gene discussed is DCT; the disease is melanoma.